Technical Assistance

Gathering and Disseminating Standardized Gene Therapy Data: The WFH Gene Therapy Registry

Author(s):

Barbara Konkle, Flora Peyvandi, Mayss Naccache, Toong Youttananukorn, Wolfgang Miesbach, Brian O’Mahony, Mike Makris, Tadashi Matsushita, Steven Pipe, Tammuella Chrisentery-Singleton, Mark Skinner, Donna Coffin, Glen Pierce
Publication:
European Association for Haemophilia and Allied Disorders (EAHAD) 17th Annual Congress 2024
Date:
February 6-9, 2024
Topics:
gene therapy, WFH Gene Therapy Registry, registry

Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network

Author(s):

Maria T. DeSancho, Erin Suvar, Jonathan C. Roberts, Michael D. Tarantino, Jonathan Schwartz, Jessica Callis, Michael Recht
Publication:
Journal of Thrombosis and Haemostasis
Date:
August 14, 2024
Topics:
thrombosis, antithrombin, hereditary antithrombin deficiency, HAD

Application of Artificial Intelligence and Machine Learning Was Not Able to Reliably Predict Poor Outcomes in People with Hemophilia

Author(s):

Jianzhong Hu, Lu Chen, Bob Rogers, Martin Chandler, Jarren Santos
Publication:
Cureus
Date:
August 13, 2024
Topics:
Hemophilia

Emicizumab and females with Hemophilia A in the ATHNdataset and prospective ATHN 7 Study

Author(s):

Tammuella Chrisentery-Singleton, Lucy Lee, Paul Morton, Michael Recht
Publication:
ISTH Congress 2024
Date:
June 22-26, 2024
Topics:
emicizumab, hemophilia A, females with hemophilia A, ATHNdataset, ATHN 7

IX-TEND: A Phase IV Observational, Long-Term Follow-Up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B

Author(s):

Andreas Tiede, Blanca Salazar, Sean Gill, Paul E. Monahan, Tammuella Chrisentery-Singleton
Publication:
ISTH Congress 2024
Date:
June 22-26, 2024
Topics:
etranacogene dezaparvovec, hemophilia B, ATHN Transcends

Long-Term Safety and Effectiveness of Emicizumab in People with Hemophilia A in the Hemophilia Natural History Study (ATHN 7)

Author(s):

Michael Recht, Shannon Carpenter, Lucy Lee, Thomas McLean, Paul Morton, Janice Staber, Michael Wang, Tammuella Chrisentery-Singleton
Publication:
ISTH Congress 2024
Date:
June 22-26, 2024
Topics:
emicizumab, hemophilia A, ATHN 7

Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia

Author(s):

Jennifer H. Han, Brandi Dupervil, Arash Mahajerin, Roshni Kulkarni, Marilyn Manco-Johnson, Courtney Thornburg
Publication:
Blood Advances
Date:
June 11, 2024
Topics:
Hemophilia

Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset

Author(s):

Jianzhong Hu, Martin Chandler, Matthew Manuel, Michael Denne, Bruce Ewenstein, Ali Mokdad, Shah Xing, Michael Recht
Publication:
Journal of Blood Medicine, Volume 15: 15 pages 191-205
Date:
April 24, 2024
Topics:
Hemophilia, Bleeding

ATHN Transcends: Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Author(s):

Divyaswathi Citla Sridhar, Sanjay Ahuja, Tammuella Chrisentery-Singleton, Carrie O’Neill, Catherine Rea, Jigar Amin, Michael Recht, Meera Chitlur
Publication:
World Federation of Hemophilia (WFH) World Congress 2024
Date:
April 21-24, 2024
Topics:
ATHN Transcends, Glanzmann thrombasthenia, GT

ATHN Transcends – Hemophilia Gene Therapy Outcomes Arm: A Long-Term Follow-Up Study on Safety and Effectiveness of Gene Therapy on People with Hemophilia

Author(s):

Janice M. Staber, Blanca Salazar, Roberto Guillen-Gonzalez, Michael Recht, Tammuella Chrisentery-Singleton, Ulrike M. Reiss
Publication:
World Federation of Hemophilia (WFH) World Congress 2024
Date:
April 21-24, 2024
Topics:
ATHN Transcends, gene therapy, hemophilia

A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders

Author(s):

Tammuella Chrisentery-Singleton, Carrie O’Neill, Nana Ama Afari-Dwamena, Andrea Adeusi, Michael Recht
Publication:
World Federation of Hemophilia (WFH) World Congress 2024
Date:
April 21-24, 2024
Topics:
ATHN Transcends, blood disorders

Prevalence of Venous thromboembolism in people with inherited bleeding disorders: real-world data from the ATHNdataset

Author(s):

Shreya Agarwal, Joseph Stanek, Brian Hu, Nabil Daoud, Tammuella Chrisentery-Singleton, Vilmarie Rodriguez
Publication:
World Federation of Hemophilia (WFH) World Congress 2024
Date:
April 21-24, 2024
Topics:
venous thromboembolism, VTE, ATHNdataset

ATHN Transcends: Hemophilia Gene Therapy Outcomes Arm: A Long-Term Follow-Up Study on Safety and Effectiveness of Gene Therapy on People with Hemophilia

Author(s):

Janice Staber, Blanca Salazar, Roberto Guillen-Gonzalez, Michael Recht, Tammuella Chrisentery-Singleton, Ulrike Reiss
Publication:
Thrombosis & Hemostasis Summit of North America (THSNA) 2024
Date:
April 4-6, 2024
Topics:
ATHN Transcends, gene therapy, hemophilia

Real-World Efficacy Data on Adolescent Hemophilia A Patients Transitioning to BAY 81-8973 or BAY 94-9027 in the ATHNdataset

Author(s):

Michael Recht, Jessica Charlet, Thomas Moulton
Publication:
Thrombosis & Hemostasis Summit of North America (THSNA) 2024
Date:
April 4-6, 2024
Topics:
hemophilia A, inhibitors, prophylaxis, ATHNdataset

ATHN Transcends: Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Author(s):

Divyaswathi Citla-Sridhar, Sanjay Ahuja, Tammuella Chrisentery-Singleton, Carrie O’Neill, Catherine Rae, Jigar Amin, Michael Recht, Meera Chitlur
Publication:
Thrombosis & Hemostasis Summit of North America (THSNA) 2024
Date:
April 4-6, 2024
Topics:
ATHN Transcends, Glanzmann thrombasthenia, GT

Can’t find what you’re looking for?
Please contact support@athn.org for assistance.